Christopher G. Smith
Christopher G. Smith
Dr
Verified email at cruk.cam.ac.uk
Title
Cited by
Cited by
Year
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
TS Maughan, RA Adams, CG Smith, AM Meade, MT Seymour, RH Wilson, ...
The Lancet 377 (9783), 2103-2114, 2011
9602011
Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26. 2, 12q13. 13 and 20q13. 33
RS Houlston, J Cheadle, SE Dobbins, A Tenesa, AM Jones, K Howarth, ...
Nature genetics 42 (11), 973-977, 2010
3672010
Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies
S Venderbosch, ID Nagtegaal, TS Maughan, CG Smith, JP Cheadle, ...
Clinical Cancer Research 20 (20), 5322-5330, 2014
2702014
Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk
MG Dunlop, SE Dobbins, SM Farrington, AM Jones, C Palles, N Whiffin, ...
Nature genetics 44 (7), 770-776, 2012
2232012
Enhanced detection of circulating tumor DNA by fragment size analysis
F Mouliere, D Chandrananda, AM Piskorz, EK Moore, J Morris, ...
Science translational medicine 10 (466), eaat4921, 2018
1042018
A new GWAS and meta-analysis with 1000Genomes imputation identifies novel risk variants for colorectal cancer
NA Al-Tassan, N Whiffin, FJ Hosking, C Palles, SM Farrington, ...
Scientific reports 5, 10442, 2015
872015
Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy±cetuximab
CG Smith, D Fisher, B Claes, TS Maughan, S Idziaszczyk, G Peuteman, ...
Clinical Cancer Research 19 (15), 4104-4113, 2013
852013
Identification of potentially responsive subsets when cetuximab is added to oxaliplatin-fluoropyrimidine chemotherapy (CT) in first-line advanced colorectal cancer (aCRC …
TS Maughan, R Adams, CG Smith, MT Seymour, RH Wilson, AM Meade, ...
Journal of Clinical Oncology 28 (15_suppl), 3502-3502, 2010
832010
Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC …
T Maughan, RA Adams, CG Smith, MT Seymour, R Wilson, AM Meade, ...
EJC SUPPLEMENTS 7 (3), 2009
702009
Exome resequencing identifies potential tumor‐suppressor genes that predispose to colorectal cancer
CG Smith, M Naven, R Harris, J Colley, H West, N Li, Y Liu, R Adams, ...
Human mutation 34 (7), 1026-1034, 2013
572013
MRC COIN Trial Investigators: Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the …
TS Maughan, RA Adams, CG Smith, AM Meade, MT Seymour, RH Wilson, ...
Lancet 377 (9783), 2103-2114, 2011
492011
Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials
JF Seligmann, D Fisher, CG Smith, SD Richman, F Elliott, S Brown, ...
Annals of Oncology 28 (3), 562-568, 2017
472017
Mendelian randomisation analysis strongly implicates adiposity with risk of developing colorectal cancer
D Jarvis, JS Mitchell, PJ Law, K Palin, S Tuupanen, A Gylfe, UA Hänninen, ...
British journal of cancer 115 (2), 266-272, 2016
342016
Association of plasma and urinary mutant DNA with clinical outcomes in muscle invasive bladder cancer
KM Patel, KE Van Der Vos, CG Smith, F Mouliere, D Tsui, J Morris, ...
Scientific reports 7 (1), 1-12, 2017
322017
Oxaliplatin and fluoropyrimidine chemotherapy plus or minus cetuximab: the effect of infusional 5-FU or capecitabine on the outcomes of the MRC COIN trial in advanced …
TS Maughan, R Adams, CG Smith, T Seymour, RH Wilson, AM Meade
ASCO GI Cancers Symposium, 2010
322010
Mendelian randomisation implicates hyperlipidaemia as a risk factor for colorectal cancer
H Rodriguez‐Broadbent, PJ Law, A Sud, K Palin, S Tuupanen, A Gylfe, ...
International journal of cancer 140 (12), 2701-2708, 2017
282017
BRAF and NRAS locus-specific variants have different outcomes on survival to colorectal cancer
MG Summers, CG Smith, TS Maughan, R Kaplan, V Escott-Price, ...
Clinical Cancer Research 23 (11), 2742-2749, 2017
262017
Variation at 2q35 (PNKD and TMBIM1) influences colorectal cancer risk and identifies a pleiotropic effect with inflammatory bowel disease
G Orlando, PJ Law, K Palin, S Tuupanen, A Gylfe, UA Hänninen, T Cajuso, ...
Human molecular genetics 25 (11), 2349-2359, 2016
262016
Analysis of the frequency of GNAS codon 201 mutations in advanced colorectal cancer
S Idziaszczyk, CH Wilson, CG Smith, DJ Adams, JP Cheadle
Cancer genetics and cytogenetics 202 (1), 67-69, 2010
262010
Detection of cell‐free DNA fragmentation and copy number alterations in cerebrospinal fluid from glioma patients
F Mouliere, R Mair, D Chandrananda, F Marass, CG Smith, J Su, J Morris, ...
EMBO molecular medicine 10 (12), 2018
232018
The system can't perform the operation now. Try again later.
Articles 1–20